Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

For MedTech and Biopharma teams considering Latin America, Brazil has historically been seen as a high-potential but hard-to-predict jurisdiction for early-stage clinical trials. That uncertainty can inflate budgets and push teams toward smaller, single-country feasibility strategies.

Brazil’s Law No. 14.874/2024 introduced a clear constraint: for primary petitions for clinical trials with humans (for marketing authorization purposes), the health analysis may not exceed 90 business days. The law also describes how additional information requests affect the clock.

This article explains what the 90-business-day window means in practical terms, how sponsors can build a sponsor-ready activation timeline around it, and what pitfalls still cause delays even in a more predictable regime.

What the law changed (and what it did not)

The most sponsor-relevant shift is that a defined review window reduces planning ambiguity. A predictable maximum review duration enables better parallelization: ethics preparation, site contracting, and supply chain setup can be scheduled against a more reliable regulatory milestone.

However, a legal review window does not automatically eliminate operational delays. Sponsors still need to manage:

• Dossier completeness and consistent technical documentation
• Ethics sequencing across institutions and committees
• Import readiness for investigational product shipments
• Site activation capacity (training, contracting, scheduling)

In other words, the “clock” helps the regulatory portion of the critical path—but the rest of the program still needs a plan.

Translating “90 business days” into an activation timeline

Sponsors often underestimate how different business days can be from calendar days when building a global timeline. A pragmatic approach is to create three layers:

• Regulatory layer: submission, review window, and potential information request handling
• Ethics layer: committee submissions and approvals (often overlapping but not identical to regulatory steps)
• Operations layer: contracts, budget approvals, training, and supply chain readiness

A sponsor-ready planning template for Brazil should include:

• Week 0–2: lock document ownership, finalize submission-ready dossier, confirm translation requirements, and run an internal quality check.
• Week 2–4: submit to the relevant bodies; initiate site contracting and budget cycles in parallel.
• During review window: implement a weekly “readiness review” covering import documentation, device labeling alignment (if applicable), training scheduling, and monitoring plans.
• Upon clearance + ethics alignment: initiate first shipment, conduct site initiation, and begin enrollment.

The objective is to avoid a common failure mode: regulatory clearance arrives, but operations are not ready—so the team loses the predictability advantage that the defined window provides.

How information requests can still create delays

Even with a defined maximum window, sponsors should plan for information requests. The practical lesson is to assume that the first submission must be as complete as possible, and that the team must be ready to respond quickly.

To reduce the chance of delays:

• Assign a single submission owner responsible for consistency across protocol, investigator brochure (if applicable), device dossier, and administrative documents.
• Create a rapid-response package before submission: technical specs, risk management summaries, labeling variants, and manufacturing documentation.
• Pre-brief sites on likely follow-up questions so responses do not stall waiting for institutional input.

Speed matters because information requests often pause progress until the sponsor responds, and slow responses can negate the benefits of the defined review period.

Why Brazil’s predictability matters for LATAM multi-country strategy

For some early-stage teams, Brazil may now be easier to include in a multi-country Latin America strategy when paired with other jurisdictions. The strategic value is not only speed—it is credibility of planning. When leadership teams can explain why the timeline is realistic, financing, vendor contracting, and site commitments become easier.

To maximize the benefit, sponsors should treat Brazil as one component of a LATAM activation architecture:

• Define a country sequencing strategy (which country starts first and why)
• Standardize document templates across countries (with country annexes)
• Build a supply chain plan that can support staggered activations without stockouts

When done well, the result is not just a faster first patient in; it is a trial program that is easier to scale.

FAQ

Does the 90-business-day window guarantee approval?

No. A defined window is about timing, not outcome. Sponsors still need a complete, well-justified dossier and an operational plan that supports ethics and site readiness.

Should early-stage sponsors wait for Brazil before activating other LATAM countries?

Not necessarily. Many sponsors can run activities in parallel across countries. The right choice depends on device complexity, supply chain constraints, and how quickly the sponsor can support multiple site activations.

What is the single biggest mistake sponsors make with “faster” regulatory timelines?

Assuming that regulatory speed automatically creates operational speed. The winning approach is to use predictability to parallelize work—contracts, training, and import readiness—so the program is ready when clearance arrives.

Bottom line: Brazil’s Law 14.874/2024 gives sponsors a more predictable planning horizon. The teams that benefit most will be the ones that treat the regulatory window as a scheduling tool—and execute the operational readiness plan in parallel.